Design and synthesis of pironetin analogue/colchicine hybrids and study of their cytotoxic activity and mechanisms of interaction with tubulin

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10391-10403

  Vilanova, Concepción ^a   Díaz Oltra, Santiago ^a   Murga, Juan ^a   Falomir, Eva ^a   Carda, Miguel ^a   Redondo Horcajo, Mariano ^b   Díaz, J Fernando ^b   Barasoain, Isabel ^b   Marco, J Alberto ^c  

^a UNIVERSITAT JAUME I   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

12 OXO 12 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]DODECANOIC ACID; 16 OXO 16 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]HEXADECANOIC ACID; 5 HYDROXY 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 12 OXO 12 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO] DODECANOATE; 5 HYDROXY 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 16 OXO 16 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO] HEXADECANOATE; 5 HYDROXY 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 5 OXO 5 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO] PENTANOATE; 5 HYDROXY 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 8 OXO 8 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO] OCTANOATE; 5 OXO 5 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]PENTANOIC ACID; 5 [(TERT BUTYLDIMETHYLSILYL)OXY] 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 12 OXO 12 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]DODECANOATE; 5 [(TERT BUTYLDIMETHYLSILYL)OXY] 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 16 OXO 16 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]HEXADECANOATE; 5 [(TERT BUTYLDIMETHYLSILYL)OXY] 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 5 OXO 5 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]PENTANOATE; 5 [(TERT BUTYLDIMETHYLSILYL)OXY] 3 METHOXY 6 [6 OXO 3,6 DIHYDRO 2H PYRAN 2 YL]HEXYL 8 OXO 8 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]OCTANOATE; 8 OXO 8 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO]OCTANOIC ACID; COLCHICINE DERIVATIVE; CYTOTOXIC AGENT; METHYL 12 OXO 12 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO] DODECANOATE; METHYL 16 OXO 16 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO] HEXADECANOATE; METHYL 8 OXO 8 [(1,2,3,10 TETRAMETHOXY 9 OXO 5,6,7,9 TETRAHYDROBENZO[A]HEPTALEN 7 YL)AMINO] OCTANOATE; MULTIDRUG RESISTANCE PROTEIN; PIRONETIN DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COLCHICINE; PIRONETIN; PYRONE DERIVATIVE;

A549 CELL LINE; ACYLATION; ADENOCARCINOMA CELL LINE; ARTICLE; BINDING SITE; BREAST ADENOCARCINOMA; CELL CYCLE; CELL GROWTH; CHEMICAL INTERACTION; COLON ADENOCARCINOMA; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY ASSAY; DEPOLYMERIZATION; DESILYLATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; G2 PHASE CELL CYCLE CHECKPOINT; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; IMMUNOFLUORESCENCE; MCF 7 CELL LINE; METAPHASE; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MITOSIS SPINDLE; NON SMALL CELL LUNG CANCER; NUCLEOPHILICITY; OVARY CARCINOMA; PROTEIN EXPRESSION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NEOPLASMS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL PROLIFERATION; COLCHICINE; DRUG DESIGN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROTUBULES; MOLECULAR STRUCTURE; NEOPLASMS; PYRONES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUMOR CELLS, CULTURED;

EID: 84920171406     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501112q     Document Type: Article

References (79)

1. Garcia, M.; Jemal, A.; Ward, E. M.; Center, M. M.; Hao, Y.; Siegel, R. L.; Thun, M. J. Global Cancer Facts & Figures 2007; American Cancer Society: Atlanta, GA, 2007.
2. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer Cell 2000, 100, 57-70
3. Stratton, M. R.; Campbell, P. J.; Futreal, P. A. The cancer genome Nature 2009, 458, 719-724
4. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer: the next generation Cell 2011, 144, 646-674
5. Boyle, F. T.; Costello, G. F. Cancer therapy: a move to the molecular level Chem. Soc. Rev. 1998, 27, 251-261
6. Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer research Science 2000, 287, 1969-1973
7. Penn, L. Z. Apoptosis modulators as cancer therapeutics Curr. Opin. Invest. Drugs 2001, 2, 684-692
8. Zhou, B.; Liu, Z.-L. Bioantioxidants: from chemistry to biology Pure Appl. Chem. 2005, 77, 1887-1903
9. Park, H.-J.; Jung, H.-J.; Lee, K.-T.; Choi, J. Biological characterization of the chemical structures of naturally occurring substances with cytotoxicity Nat. Prod. Sci. 2006, 12, 175-192
10. Portt, L.; Norman, G.; Clapp, C.; Greenwood, M.; Greenwood, M. T. Anti-apoptosis and cell survival: a review Biochim. Biophys. Acta, Mol. Cell Res. 2011, 1813, 238-259
11. Torres-Andón, F.; Fadeel, B. Programmed cell death: molecular mechanisms and implications for safety assessment of nanomaterials Acc. Chem. Res. 2013, 46, 733-742
12. Sánchez-Pedregal, V. M.; Griesinger, C. The tubulin binding mode of MT stabilizing and destabilizing agents studied by NMR Top. Curr. Chem. 2009, 286, 151-208
13. Nettles, J. H.; Downing, K. H. The tubulin binding mode of microtubule stabilizing agents studied by electron crystallography Top. Curr. Chem. 2009, 286, 209-257
14. Botta, M.; Forli, S.; Magnani, M.; Manetti, F. Molecular modeling approaches to study the binding mode on tubulin of microtubule destabilizing and stabilizing agents Top. Curr. Chem. 2009, 286, 279-328
15. Alushin, G. M.; Lander, G. C.; Kellogg, E. H.; Zhang, R.; Baker, D.; Nogales, E. High-resolution microtubule structures reveal the structural transitions in αβ-tubulin upon GTP hydrolysis Cell 2014, 157, 1117-1129
16. Chen, J.; Liu, T.; Dong, X.; Hu, Y. Recent development and SAR analysis of colchicine binding site inhibitors Mini-Rev. Med. Chem. 2009, 9, 1174-1190
17. Van der Heijden, R.; Jacobs, D. I.; Snoeijer, W.; Hallard, D.; Verpoorte, R. The Catharanthus alkaloids: pharmacognosy and biotechnology Curr. Med. Chem. 2004, 11, 607-628
18. Keglevich, P.; Hazai, L.; Kalaus, G.; Szántay, C. Modifications on the basic skeletons of vinblastine and vincristine Molecules 2012, 17, 5893-5914
19. Fu, Y.; Li, S.; Zu, Y.; Yang, G.; Yang, Z.; Luo, M.; Jiang, S.; Wink, M.; Efferth, T. Medicinal chemistry of paclitaxel and its analogs Curr. Med. Chem. 2009, 16, 3966-3985
20. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr. Med. Chem.: Anti-Cancer Agents 2002, 2, 1-17
21. Abal, M.; Andreu, J. M.; Barasoain, I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action Curr. Cancer Drug Targets 2003, 3, 193-203
22. Correia, J. J.; Lobert, S. Physiochemical aspects of tubulin-interacting antimitotic drugs Curr. Pharm. Des. 2001, 7, 1213-1228
23. Jiménez-Barbero, J.; Amat-Guerri, F.; Snyder, J. P. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization Curr. Med. Chem.: Anti-Cancer Agents 2002, 2, 91-122
24. Díaz, J. F.; Andreu, J. M.; Jiménez-Barbero, J. The interaction of microtubule with stabilizers characterized at biochemical and structural levels Top. Curr. Chem. 2009, 286, 121-149
25. Gigant, B.; Cormier, A.; Dorléans, A.; Ravelli, R. B. G.; Knossow, M. Microtubule-destabilizing agents: structural and mechanistic insights from the interaction of colchicine and vinblastine with tubulin Top. Curr. Chem. 2009, 286, 259-278
26. Daly, E. M.; Taylor, R. E. Entropy and enthalpy in the activity of tubulin-based antimitotic agents Curr. Chem. Biol. 2009, 3, 367-379
27. Sarabia, F.; García-Castro, M.; Sánchez-Ruiz, A. Chemistry and biology of novel microtubule-destabilizing agents that bind α-tubulin Curr. Bioact. Compd. 2006, 2, 269-299
28. Anderson, H. J.; Coleman, J. E.; Andersen, R. J.; Roberge, M. Cytotoxic peptides hemiasterlin, hemiasterlin A, and hemiasterlin B include mitotic arrest and abnormal spindle formation Cancer Chemother. Pharmacol. 1997, 39, 223-226
29. Kondoh, M.; Usui, T.; Kobayashi, S.; Tsuchiya, K.; Nishikawa, K.; Nishikiori, T.; Mayumi, T.; Osada, H. Cell cycle arrest and antitumor activity of pironetin and its derivatives Cancer Lett. 1998, 126, 29-32
30. Kondoh, M.; Usui, T.; Nishikiori, T.; Mayumi, T.; Osada, H. Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin Biochem. J. 1999, 340, 411-416
31. Watanabe, H.; Watanabe, H.; Usui, T.; Kondoh, M.; Osada, H.; Kitahara, T. Synthesis of pironetin and related analogs: studies on structure-activity relationships as tubulin assembly inhibitors J. Antibiot. 2000, 53, 540-545
32. Usui, T.; Watanabe, H.; Nakayama, H.; Tada, Y.; Kanoh, N.; Kondoh, M.; Asao, T.; Takio, K.; Watanabe, H.; Nishikawa, K.; Kitahara, T.; Osada, H. The anticancer natural product pironetin selectively targets Lys352 of α-tubulin Chem. Biol. 2004, 11, 799-806
33. Marco, J. A.; Carda, M.; Murga, J.; Falomir, E. Stereoselective syntheses of naturally occurring 5,6-dihydropyran-2-ones Tetrahedron 2007, 63, 2929-2958
34. Marco, J. A.; Carda, M. Recent advances in the field of naturally occurring 5,6-dihydropyran-2-ones. In Natural Lactones and Lactams. Synthesis, Occurrence and Biological Activity; Janecki, T., Ed.; Wiley-VCH: Weinheim, Germany, 2014; pp 51-100.
35. Kavallaris, M. Microtubules and resistance to tubulin-binding agents Nat. Rev. Cancer 2010, 10, 194-204
36. Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G. Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 2013, 13, 714-726
37. Rossi, L. M.; Rangasamy, P.; Zhang, J.; Qiu, X.-Q.; Wu, G. Y. Research advances in the development of peptide antibiotics J. Pharm. Sci. 2007, 97, 1060-1070
38. Courvalin, P. Predictable and unpredictable evolution of antibiotic resistance J. Intern. Med. 2008, 264, 4-16
39. Gualtieri, M.; Baneres-Roquet, F.; Villain-Guillot, P.; Pugniere, M.; Leonetti, J.-P. The antibiotics in the chemical space Curr. Med. Chem. 2009, 16, 390-393
40. Yasui, K.; Tamura, Y.; Nakatani, K.; Kawada, K.; Ohtani, M. Total synthesis of (-)-PA-48153C, a novel immunosuppressive 2-pyranone derivative J. Org. Chem. 1995, 60, 7567-7574
41. Gurjar, M. K.; Henri, J. T., Jr.; Bose, D. S.; Rao, A. V. R. Total synthesis of a potent immunosuppressant pironetin Tetrahedron Lett. 1996, 37, 6615-6618
42. Chida, N.; Yoshinaga, M.; Tobe, T.; Ogawa, S. Total synthesis of (-)-PA-48153C (pironetin) utilising l-quebrachitol as a chiral building block Chem. Commun. 1997, 1043-1044
43. Watanabe, H.; Watanabe, H.; Bando, M.; Kido, M.; Kitahara, T. An efficient synthesis of pironetins employing a useful chiral building block, (1 S,5 S,6 R)-5-hydroxybicyclo[4.1.0]heptan-2-one Tetrahedron 1999, 55, 9755-9776
44. Keck, G. E.; Knutson, C. E.; Wiles, S. A. Total synthesis of the immunosupressant (-)-pironetin (PA48153C) Org. Lett. 2001, 3, 707-710
45. Dias, L. C.; de Oliveira, L. G.; de Sousa, M. A. Total synthesis of (-)-pironetin Org. Lett. 2003, 5, 265-268
46. Shen, X.; Wasmuth, A. S.; Zhao, J.; Zhu, C.; Nelson, S. G. Catalytic asymmetric assembly of stereodefined propionate units: an enantioselective total synthesis of (-)-pironetin J. Am. Chem. Soc. 2006, 128, 7438-7439
47. Enders, D.; Dhulut, S.; Steinbusch, D.; Herrbach, A. Asymmetric total synthesis of (-)-pironetin employing the SAMP/RAMP hydrazone methodology Chem.-Eur. J. 2007, 13, 3942-3949
48. Bressy, C.; Vors, J.-P.; Hillebrand, S.; Arseniyadis, S.; Cossy, J. Asymmetric total synthesis of the immunosuppressant (-)-pironetin Angew. Chem., Int. Ed. 2008, 47, 10137-10140
49. Crimmins, M. T.; Dechert, A.-M. R. Enantioselective total synthesis of (-)-pironetin: iterative aldol reactions of thiazolidinethiones Org. Lett. 2009, 11, 1635-1638
50. Yadav, J. S.; Ather, H.; Rao, N. V.; Reddy, M. S.; Prasad, A. R. Stereoselective synthesis of (-)-pironetin by an iterative Prins cyclisation and reductive cleavage strategy Synlett 2010, 1205-1208
51. Marco, J. A.; García-Pla, J.; Carda, M.; Murga, J.; Falomir, E.; Trigili, C.; Notararigo, S.; Díaz, J. F.; Barasoain, I. Design and synthesis of pironetin analogues with simplified structure and study of their interactions with microtubules Eur. J. Med. Chem. 2011, 46, 1630-1637
52. Carda, M.; Murga, J.; Díaz-Oltra, S.; García-Pla, J.; Paños, J.; Falomir, E.; Trigili, C.; Díaz, J. F.; Barasoain, I.; Marco, J. A. Synthesis and biological evaluation of α-tubulin-binding pironetin analogues with enhanced lipophilicity Eur. J. Org. Chem. 2013, 1116-1123
53. Paños, J.; Díaz-Oltra, S.; Sánchez-Peris, M.; García-Pla, J.; Murga, J.; Falomir, E.; Carda, M.; Redondo-Horcajo, M.; Díaz, J. F.; Barasoain, I.; Marco, J. A. Synthesis and biological evaluation of truncated α-tubulin-binding pironetin analogues lacking alkyl pendants in the side chain or the dihydropyrone ring Org. Biomol. Chem. 2013, 11, 5809-5826
54. Vilanova, C. Ph.D. Thesis, Universitat Jaume I, December 2013.
55. Hanessian, S. Structure-based organic synthesis of drug prototypes: a personal odyssey ChemMedChem 2006, 1, 1300-1330
56. Meunier, B. Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res. 2008, 41, 69-77
57. Decker, M. Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond Curr. Med. Chem. 2011, 18, 1464-1475
58. Bombuwala, K.; Kinstle, T.; Popik, V.; Uppal, S. O.; Olesen, J. B.; Viña, J.; Heckman, C. A. Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel. Beilstein J. Org. Chem. 2006, 2, No. 13.
59. Sharifi, N.; Hamel, E.; Lill, M. A.; Risbood, P.; Kane, C. T., Jr.; Hossain, M. T.; Jones, A.; Dalton, J. T.; Farrar, W. L. A bifunctional colchicinoid that binds to the androgen receptor Mol. Cancer Ther. 2007, 6, 2328-2336
60. Zefirova, O. N.; Nurieva, E. V.; Shishov, D. V.; Bashkin, I. I.; Fuchs, F.; Lemcke, H.; Schröder, F.; Weiss, D. G.; Zefirov, N. S.; Kuznetsov, S. A. Synthesis and SAR requirements of adamantane-colchicine conjugates with both microtubule depolymerizing and tubulin clustering activities Bioorg. Med. Chem. 2011, 19, 5529-5538
61. Malysheva, Y. B.; Combes, S.; Allegro, D.; Peyrot, V.; Knochel, P.; Gavryushin, A. E.; Fedorov, A. Y. Synthesis and biological evaluation of novel anticancer bivalent colchicine-tubulizine hybrids Bioorg. Med. Chem. 2012, 20, 4271-4278
62. Zhang, X.; Zhang, J.; Tong, L.; Luo, Y.; Su, M.; Zang, Y.; Li, J.; Lu, W.; Chen, Y. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents Bioorg. Med. Chem. 2013, 21, 3240-3244
63. Bagnato, J. D.; Eilers, A. L.; Horton, R. A.; Grissom, C. B. Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin J. Org. Chem. 2004, 69, 8987-8996
64. Torijano-Gutiérrez, S.; Vilanova, C.; Díaz-Oltra, S.; Murga, J.; Falomir, E.; Carda, M.; Marco, J. A. Design and synthesis of pironetin analogue/combretastatin A-4 hybrids and evaluation of their cytotoxic activity Eur. J. Org. Chem. 2014, 2284-2296
65. Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. A rapid esterification by mixed anhydride and its application to large-ring lactonization Bull. Chem. Soc. Jpn. 1979, 52, 1989-1993
66. Arden, N.; Betenbaugh, M. J. Life and death in mammalian cell culture: strategies for apoptosis inhibition Trends Biotechnol. 2004, 22, 174-180
67. Gadgeel, S. M. New targets in non-small cell lung cancer Curr. Oncol. Rep. 2013, 15, 411-423
68. Jordan, M. A.; Thrower, D.; Wilson, L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis J. Cell Sci. 1992, 102, 401-416
69. Oosawa, F.; Asakura, S. Thermodynamics of the Polymerization of Proteins; Academic Press: London, 1975.
70. Buey, R. M.; Calvo, E.; Barasoain, I.; Pineda, O.; Edler, M. C.; Matesanz, R.; Cerezo, G.; Vanderwal, C. D.; Day, B. W.; Sorensen, E. J.; López, J. A.; Andreu, J. M.; Hamel, E.; Díaz, J. F. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites Nat. Chem. Biol. 2007, 3, 117-125
71. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202
72. Sun, L.; Hamel, E.; Lin, C. M.; Hastie, S. B.; Pyluck, A.; Lee, K. H. Antitumor agents. 141. Synthesis and biological evaluation of novel thiocolchicine analogs: N -acyl, N -aroyl-, and N -(substituted benzyl)-deacetylthiocolchicines as potent cytotoxic and antimitotic compounds J. Med. Chem. 1993, 36, 1474-1479
73. Bhattacharyya, B.; Howard, R.; Maity, S. N.; Brossi, A.; Sharma, P. N.; Wolff, J. B ring regulation of colchicine binding kinetics and fluorescence Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 2052-2055
74. Meksuriyen, D.; Lin, L. J.; Cordell, G. A.; Mukhopadhyay, S.; Banerjee, S. K. NMR Studies of colchicine and its photoisomers, β- and γ-lumicolchicines J. Nat. Prod. 1988, 51, 88-93
75. Rodríguez-Nieto, S.; Medina, M. A.; Quesada, A. R. A re-evaluation of fumagillin selectivity towards endothelial cells Anticancer Res. 2001, 21, 3457-3460
76. Yang, C.; Barasoain, I.; Li, X.; Matesanz, R.; Liu, R.; Sharom, F. J.; Yin, D. L.; Díaz, J. F.; Fang, W. S. Overcoming tumor drug resistance mediated by P-glycoprotein overexpression with high affinity taxanes: a SAR study of C-2 modified 7-acyl-10-deacetilcephalomannines ChemMedChem 2007, 2, 691-701
77. De Ines, C.; Leynadier, D.; Barasoain, I.; Peyrot, V.; Garcia, P.; Briand, C.; Rener, G. A.; Temple, C., Jr. Inhibition of microtubules and cell-cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI-980, and by its chiral isomer, NSC-613863 Cancer Res. 1994, 54, 75-84
78. Andreu, J. M.; Barasoain, I. The interaction of baccatin III with the taxol binding site of microtubules determined by a homogeneous assay with fluorescent taxoid Biochemistry 2001, 40, 11975-11984
79. Buey, R. M.; Barasoain, I.; Jackson, E.; Meyer, A.; Giannakakou, P.; Paterson, I.; Mooberry, S.; Andreu, J. M.; Díaz, J. F. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity Chem. Biol. 2005, 12, 1269-1279